Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach

por Achilonu, Ikechukwu, Iwuchukwu, Emmanuel Amarachi, Achilonu, Okechinyere Juliet, Fernandes, Manuel Antonio, Sayed, Yasien
Publicado 2020